Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women.

CONTEXT Low bone mineral density (BMD) is commonly reported in young men and women with HIV infection, and fracture rates may be higher. With effective antiretroviral therapy (ART), the HIV population is aging. However, little is known about the skeletal status of postmenopausal women. OBJECTIVE We aimed to assess the effects of HIV infection and ART on BMD and bone turnover in postmenopausal minority women. DESIGN, SETTING, AND PATIENTS A prospective cohort study was performed in 92 HIV+ and 95 HIV- postmenopausal Hispanic and African-American women. MAIN OUTCOME MEASURES We measured BMD by dual-energy x-ray absorptiometry, fracture prevalence, serum levels of inflammatory cytokines (TNFalpha, IL-6), bone turnover markers, calciotropic hormones, and estrone. RESULTS HIV+ women were younger (56 +/- 1 vs. 60 +/- 1 yr; P < 0.01) and had lower BMI (28 +/- 1 vs. 30 +/- 1 kg/m(2); P < 0.01) and estrone levels. Prevalence of T scores below -1.0 was greater in HIV+ women at the spine (78 vs. 64%; P < 0.05), total hip (45 vs. 29%; P < 0.05), and femoral neck (64 vs. 46%; P < 0.05), and Z scores adjusted for BMI were lower in HIV+ women at the same sites. Serum TNFalpha, N-telopeptide, and C-telopeptide were significantly higher in HIV+ than HIV- women, particularly those receiving ART. HIV+ status was independently and negatively associated with spine and hip BMD after adjustment for age, ethnicity, BMI, and alcohol. CONCLUSION The lower BMD, higher prevalence of low BMD, and higher levels of bone turnover markers detected in HIV+ postmenopausal minority women could place them at high risk for future fractures.

[1]  M. King,et al.  Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen , 2009, Journal of acquired immune deficiency syndromes.

[2]  C. Katlama,et al.  Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. , 2009, AIDS.

[3]  S. Silverman,et al.  International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. , 2008, Bone.

[4]  T. Brown,et al.  Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. , 2008, The Journal of clinical endocrinology and metabolism.

[5]  S. Wallenstein,et al.  Risk factors for decreased bone density and effects of HIV on bone in the elderly , 2008, Osteoporosis International.

[6]  I. Reid,et al.  CLINICAL Review # : low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. , 2007, The Journal of clinical endocrinology and metabolism.

[7]  V. Luther,et al.  HIV infection in older adults. , 2007, Clinics in geriatric medicine.

[8]  A. Cheng,et al.  The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected Patients , 2007, HIV clinical trials.

[9]  Y. Lo,et al.  Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection , 2007, AIDS.

[10]  T. Brown,et al.  Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review , 2006, AIDS.

[11]  S. Grinspoon,et al.  Longitudinal analysis of bone density in human immunodeficiency virus-infected women. , 2006, The Journal of clinical endocrinology and metabolism.

[12]  I. Reid,et al.  Bone mineral density is not reduced in HIV‐infected Caucasian men treated with highly active antiretroviral therapy , 2006, Clinical endocrinology.

[13]  J. Arnsten,et al.  HIV infection and bone mineral density in middle-aged women. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  E. Shane,et al.  Bone mass and mineral metabolism in HIV+ postmenopausal women , 2005, Osteoporosis International.

[15]  Michael W.-H. Wang,et al.  The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. , 2004, The Journal of clinical investigation.

[16]  Jeannie S. Huang,et al.  Reduced bone density in HIV-infected women , 2004, AIDS.

[17]  J. Laurence,et al.  HIV Envelope gp120-mediated Regulation of Osteoclastogenesis via Receptor Activator of Nuclear Factor κB Ligand (RANKL) Secretion and Its Modulation by Certain HIV Protease Inhibitors through Interferon-γ/RANKL Cross-talk* , 2003, Journal of Biological Chemistry.

[18]  L. Bergoglio,et al.  Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy , 2003, AIDS.

[19]  R. Bretzel,et al.  Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. , 2003, The Journal of infection.

[20]  K. Yarasheski,et al.  Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  L. Tatò,et al.  Altered bone metabolism in children infected with human immunodeficiency virus , 2003, Acta paediatrica.

[22]  J. Kanis,et al.  Diagnosis of osteoporosis and assessment of fracture risk , 2002, The Lancet.

[23]  J. Lenhard,et al.  Select HIV Protease Inhibitors Alter Bone and Fat Metabolismex Vivo * , 2002, The Journal of Biological Chemistry.

[24]  A. Klibanski,et al.  Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. , 2001, The Journal of clinical endocrinology and metabolism.

[25]  X. Nogués,et al.  Osteopenia in HIV-infected patients: is it the disease or is it the treatment? , 2001, AIDS.

[26]  J. Eisman,et al.  Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy , 2001, AIDS.

[27]  K. Yarasheski,et al.  Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy , 2000, AIDS.

[28]  Y. Taketani,et al.  A possible role of estrone produced in adipose tissues in modulating postmenopausal bone density. , 1995, Maturitas.

[29]  Robert Epstein,et al.  Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  Ann A. Hertzler,et al.  A dietary calcium rapid assessment method (RAM) , 1994 .

[31]  J. Halter,et al.  Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  A. Justice,et al.  Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  J. Bollerslev,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Decreased Bone Formative and Enhanced Resorptive Markers in Human Immunodeficiency Virus Infection: Indication of Normalization of the Bone-Remode , 2022 .